Consun Pharmaceutical Group (HKG:1681) said the first cohort of subjects has been successfully dosed with its renal disease drug SK-08 Tablet, according to a Thursday filing with the Hong Kong bourse.
The drug, which is currently in Phase I clinical trials, is for chronic kidney disease. It rectifies the underlying issues with kidney health to avoid complicated treatments like dialysis.
The pharmaceutical's shares were up nearly 4% at the end of trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments